Kuraray’s Post

ICYMI: Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions. (via Nature) https://lnkd.in/e8-xyX-b

ICYMI: Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions. (via Nature) https://lnkd.in/e8-xyX-b

ICYMI: Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions. (via Nature) https://lnkd.in/e8-xyX-b

It is out there, the final version of our latest contribution to the field of platelet based therapies. We aimed at characterizing platelet rich plasma (PRP) produced using a standardized closed system method, at the molecular and functional level; but we travelled a bit further, and did the same analysis with PRP subfractions, in a comparative manner. This led us to develop an optimized method to produce platelet secretomes, a platelet derived bioproduct enriched in the platelet bioactive content, and free of plasma (IP at national phase application in several countries). Thanks to the Team work behind it, this bioproduct constitutes the first line of R+D+i by PlaBiTe.

I´m excited to announced that our latest article has been published in Acta Biomaterialia! Our research aims to provide a comprehensive molecular and functional characterization of Platelet-based Bioproducts and subfractions, including Platelet-Rich Plasma (PRP), plasma fractions and Platelet Secretomes produced with a novel methodology developed by our group (PCT/IB2022/057936). Our results show that the molecular composition of each fraction correlates with its regenerative capacity in vitro. This study lays the foundations to continue delving into the idea of using Platelet Secretomes for therapeutic purposes and, given its characteristics, as an alternative to the current autologous platelet-based therapies in regenerative medicine. The following developing phases will be carried out by Platelet Biotechnologies S.L. (PlaBiTe), our recently created Spinoff company. FINBA and Universidad de Oviedo. I´m very grateful to all the collaborators, and especially to Laura Gutiérrez (IP at Platelet Research Lab – ISPA and CSO at PlaBiTe) for guiding this work from its beginnings. Check out the complete article 👇 https://lnkd.in/d483v4dK #Platelets #Secretome #RegenerativeMedicine #Biotech

𝗔 𝗖𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝗚𝘂𝗶𝗱𝗲 𝗼𝗻 Biopreservation Market  📚 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝘁𝗵𝗶𝘀 𝗣𝗗𝗙 𝗮𝘁: https://lnkd.in/dPHJhXpn  "#Biopreservation Market by Type (Media (Sera), Equipment (Thawing Equipment, Alarms, #Freezers)), #Biospecimen (Human Tissue, #StemCells, Organs), Application (Therapeutic, Research, #ClinicalTrials), End User (Hospitals, Biobank) - Global Forecast to 2025", is projected to reach USD 4.9 billion by 2025 from USD 3.1 billion in 2020, at a CAGR of 9.1% between 2020 and 2025. - The biopreservation media segment accounted for the largest share of the biopreservation media and equipment market. - The #humantissue samples segment accounted for the largest share of the biopreservation media and equipment market in 2019. - North America to dominate the biopreservation media and equipment market during the forecast period North America dominated the biopreservation media and equipment market, followed by Europe. The major factors driving the growth of this market include increasing research activities in the field of regenerative medicine, rising R&D investment in life sciences research and growing awareness of personalized medicine. Thermo Fisher Scientific, Merck Group, Avantor, ThermoGenesis Holdings, Inc., Bio-Techne, BioLife Solutions, Inc., Exact Sciences, Worthington Industries, and Chart Industries, Inc.

The book covers the use of nanoparticles in therapeutics, diagnostics, and drug delivery. Topics covered include nanomaterial fabrication, surface modification and applications; toxicity of plant-based nanomaterials; the use of herbal extracts; bioimaging; metal doped nanoparticles for drug delivery; nanoparticles designed for specific neurodegenerative conditions; theranostic nanoparticles in treating lung diseases; and glioma nanotherapy. The eBook and full color print book versions are available at: https://lnkd.in/eYVtjiRN Published by Materials Research Forum LLC, USA #materialsscience #materialsresearch #nanomaterials #nanoparticles #drugdelivery #nanotherapy

Three-dimensional human intestinal organoids (hIO) are widely used as a platform for biological and biomedical research. Read this exciting paper on how to establish and functionalizing human intestinal organoids for drug development, regenerative medicine, and biological investigations, using key "in-house" media formulations. #3D Cell Culture #MerckReagents #CuriousMinds

As one of the most closely watched development areas in the current IVD (in vitro diagnostics) field, #Alzheimer's Disease (AD) development is quite challenging and unique. Choosing a good immunological raw material can save a lot of development time and result in higher-quality immunodiagnostic reagents. To aid in this crucial process, we have compiled a list of 17 companies that possess #AD reagents: Bioeast Absea Bio HKIG Immune Technology SEEBIO MBL BEIJING BIOTECH BIOSS Dia-up Biotech ACROBiosystems Group PTM BIO Genscript Biogot Technology Med Trace Suzhou RenDuan Biological Medicine Technology Univ-bio Shanghai Linc-Bio Science HyTest Meridian Bioscience #AD #IVDCHINA #ALZHEIMER #IVDMATERIALS

The prestigious global publishing house, i.e. Elsevier "Journal of Molecular Structure," with an Impact Factor of 3.8 and a Citation Score of 6, has published our article on a novel potential synthetic therapeutic agent against hepatocellular carcinoma. We are pleased to be able to do so. Based on multiple spectroscopic evaluations, a flexible bioinspired metallocatalyst was synthesized and discovered to be a deformed octahedral complex. The XRD analysis reveals a monoclinic system with space group C 2/c. Non-classical intramolecular H-bonds stabilize its dimeric character. An in vitro investigation supported by molecular docking reveals significant dose-dependent anti-leukemic action against the Hep-G2 cell line (GI50 ˂10 g/mL).